1312 Identification and validation of immunogenic clonal neoantigens for personalized therapies

• Andrew Craig,
• Martin Forster,
• Samra Turajlic,
• Sergio A Quezada,
• Katy Newton,
• Karl Peggs,
• Fong Chan,
• Karen Matthews,
• Theres Oakes,
• Gareth Wilson,
• Elizabeth Larose Cadieux,
• Max Salm,
• Hugh O’Brien

Affiliations

Andrew Craig

vice chair, Balham, Tooting, and Wandsworth Primary Care Group

Martin Forster

9 NIHR UCLH Clinical Research Facility, London, UK

Samra Turajlic

Renal and Skin Units, Royal Marsden NHS Foundation Trust, London, UK

Sergio A Quezada

Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK

Katy Newton

Department of Surgery, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK

Karl Peggs

7 Department of Clinical Haematology, University College London Hospitals NHS Foundation Trust, London, UK

Fong Chan

1Achilles Therapeutics, London, UK

Karen Matthews

patient partner, Patient and Public Involvement Group

Theres Oakes

1Achilles Therapeutics UK Ltd, London, UK

Gareth Wilson

1Achilles Therapeutics, London, UK

Elizabeth Larose Cadieux

1Achilles Therapeutics, London, UK

Max Salm

1Achilles Therapeutics, London, UK

Hugh O’Brien

1Achilles Therapeutics, London, UK